Palavras-chave
Como Citar
Resumo
.
Referências
Egawa N, Doorbar J. The
low-risk papillomaviruses. Virus
res. 2017;231:119-27.
Lorenzi AT, Syrjänen KJ, LongattoFilho A. Human papillomavirus (HPV)
screening and cervical cancer burden. A Brazilian perspective. Virology
journal. 2015 Dec;12(1):112.
Doorbar J, Egawa N, Griffin H, Kranjec
C, Murakami I. Human papillomavirus
molecular biology and disease association.
Rev. med. virol. 2015;25:2-23.
Oliveira CM, Levi JE. The Biological
Impact of Genomic Diversity in
Cervical Cancer Development.
Acta cytol. 2016; 60(6):513-17.
Van Ham MAPC, Melchers WJG,
Hanselaar AGJM, Bekkers RLM, Boonstra
H, Massuger LFAG. Fluctuations
in prevalence of cervical human
papillomavirus in women frequently
sampled during a single menstrual cycle.
Br. j. cancer. 2002; 87(4):373-76.
International Agency for Research on
Cancer. Working Group on the Evaluation
of Carcinogenic Risks to Humans.
Human Papillomaviruses. Lyon, France:
World Health Organization; 1995.
IARC Monographs on the Evaluation of
Carcinogenic Risks to Humans.;64.
Souza N, Melo V, Castro L. Diagnóstico
da infecção pelo HPV em lesões do
colo do útero em mulheres HIV+:
acuidade da histopatologia. Rev. bras.
ginecol. obstet. 21;23(6):355-61.
Tavassoli F, Deville P. World Health
Organization Classification of Tumours.
Pathology & Genetics. Tumours of the
Breast and Female Genital Organs. Lyon,
France: IARC Press. p. 233-6, 2003.
Carvalho JJM, Oyakawa N. I
Consenso Brasileiro de HPV. São
Paulo: BG Cultural; 2000.
Downes MR. Review of in situ
and invasive penile squamous cell
carcinoma and associated non-neoplastic
dermatological conditions. J. clin.
pathol. 2015; 68:333-40.
Linhares AC, Villa LL. Vacinas contra
rotavírus e papilomavírus humano (HPV).
J Pediatr. 2006 Jul;82(3):25-34.
Modesto VL, Gottesman L. Sexually
transmitted diseases and anal
manifestations of AIDS. Surg. clin.
North America. 1994;74(6):1433-64.
Zaravinos A, Mammas IN, Sourvinos
G, Spandidos DA. Molecular detection
methods of human papillomavirus (HPV).
Int. j. biol. markers. 2009; 24(4):215-22.
Ming Guo, Gong Y, Deavers M et al.
Evaluation of a Commercialized In Situ
Hybridization Assay for Detecting Human
Papillomavirus DNA in Tissue Specimens
from Patients with Cervical Intraepithelial
Neoplasia and Cervical Carcinoma. J.
clin. microbiol. 2008; 46(1):274-80.
Steinau M, Onyekwuluje JM, Scarbrough
MZ et al. Performance of Commercial
Reverse Line Blot Assays for Human
Papillomavirus Genotyping. J. clin.
microbial. 2012; 50(5):1539-44.
Iftner T, Villa LL. Chapter 12:
Human Papillomavirus Technologies
current technology for human
papillomavirus dna detection of genital
infections. v.31, p.80-8, 2003.
Siadat-Pajouh M, Ayscue Ah,
Periasamy AHB. Introduction of a
fast and sensitive fluorescent in situ
hybridization method for single-copy
detection of human papillomavirus
(HPV) genome. J. histochem.
cytochem. 1994; 42(11):1503-12.
Vidal FCB, Nascimento MDSB, Ferraro
CTL, Brito LM. Análise crítica dos métodos
moleculares. Femina. 2012; 40:263-7.
Uhlig K, Earley A, Lamont J, Dahabreh IJ,
Avendano EE, Cowan JMFS. Fluorescence
in situ hybridization (FISH) or other
in situ hybridization (ISH) testing of uterine cervical cells to predict precancer
and cancer. Rockville (MD): Agency
for Healthcare Research and Quality.
Technology Assessment Report; 2013.
Bagarelli LB, Oliani AH. Tipagem e
estado físico de papilomavírus humano
por hibridização in situ em lesões
intra-epiteliais do colo uterino. Human
Papillomavirus Typing and Physical
State by in situ Hybridization in Uterine
Cervix Intraepithelial Lesions. Trabalhos
Originais. 2004; 26(261):59-64.
Montag M, Blankenstein TJ, Shabani N,
Bruning A, Mylonas I. Evaluation of two
commercialised in situ hybridisation
assays for detecting HPV-DNA in
formalin-fixed, paraffin-embedded
tissue. Arch. gynecol. obstet.
; 284(4):999 1005.
Warford A. In situ hybridisation:
technologies and their application to
understanding disease. Prog. histochem.
cytochem. 2016; 50(4):37-48.
Laabidi B, Ben Rejeb S, Bani A, Mansouri
N, Lamine O, Bouzaini A et al. Human
papillomavirus detection using in situ
hybridization and correlations with
histological and cytological findings.
Med. mal. infect. 2016; 46(7):380-84.
Mendez-Pena JE, Sadow PM, Nose
V, Hoang MP. A chromogenic in situ
hybridization assay with clinical
automated platform is a sensitive
method in detecting high-risk human
papillomavirus in squamous cell
carcinoma. Hum. pathol. 2017; 63:184-9.
Kimura LM, Shirata NK, Nonogaki
S, Guerra JM, Oyafuso MS, Menezes
Y, et al. Padronização do protocolo de
hibridização in situ cromogênica (CISH)
para detecção de HPV de alto e baixo
risco com a utilização da sonda comercial
marcada com digoxigenina. BEPA,
Bol. epidemiol. paul. 2017; 14:1-11.
Molijn A, Jenkins D, Chen W, Zhang
X, Pirog E, Enqi W, et al. The complex
relationship between human papillomavirus
and cervical adenocarcinoma. Int.
j. cancer. 2016; 138(2):409-16.
Tyring Sk. Human papillomavirus
infections: epidemiology, pathogenesis,
and host immune response. J. Am.
Acad. Dermatol. 2000; 43(1):18-26.
Birner P, Bachtiary B, Dreier B et al.
Signal-Amplified Colorimetric In Situ
Hybridization for Assessment of Human
Papillomavirus Infection in Cervical
Lesions. Mod. pathol. 2001; 14(7):702-9.
Sarkar FH, Miles BJ, Plieth DHCJ.
Detection of human papillomavirus
in squamous neoplasm of the penis.
J. urol. 1992; 143(2):389-92.
Bezerra AL, Lopes A, Santiago GH et al.
Human papillomavirus as a prognostic
factor in carcinoma of the penis: analysis
of 82 patients treated with amputation
and bilateral lymphadenectomy.
Cancer. 2001; 91(12):2315-21.
Lont AP, Kroon BK, Horenblas S
et al. Presence of high-risk human
papillomavirus DNA in penile carcinoma
predicts favorable outcome in survival.
Int. j. cancer. 2006; 119:1078-73.
Lu B, Viscidi RP, Lee JH, Wu Y, Villa
LL, Lazcano-Ponce E, et al. Human
papillomavirus (HPV) 6, 11, 16, and
seroprevalence is associated with
sexual practice and age: results from
the multinational HPV Infection in Men
Study (HIM Study). Cancer epidemiol.
biomark. prev. 2011; 20(5):990-1002.
Markos A. The presentation of anogenital
cancers as sexually transmissible
infection: a case for vigilance.
Sex. health. 2007; 4(1):79-80.
34. Singhi AD, Westra WH. Comparison of
human papillomavirus in situ hybridizationand p16 immunohistochemistry
in the detection of human
papillomavirus‐associated head
and neck cancer based on a
prospective clinical experience.
Cancer. 2010; 116(9):2166-73.
35. Jitani AK, Raphael V, Mishra J,
Shunyu NB, Khonglah Y, Medhi J.
Analysis of human papilloma virus
/18 DNA and its correlation
with p16 expression in oral cavity
squamous cell carcinoma in NorthEastern India: A chromogenic in-situ
hybridization based study. J Clin
Diagn Res. 2015; 9(8):EC04-EC07.
36. Gómez F, Picazo A, Roldán M,
Corcuera MT, Curiel I, Munoz E,
et al. Labelling pattern obtained by
non-isotopic in situ hybridization as a
prognostic factor in HPV-associated
lesions. J. pathol. 1996: 179(3):272-5.
37. Pirami L, Giache V, Becciolini
A. Analysis of HPV1 6, 18, 3 1,
and 35 DNA in pre-invasive and
invasive lesions of the uterine cervix.
J. clin. pathol. 1997; 50:600-4.
Este trabalho está licenciado sob uma licença Creative Commons Attribution 4.0 International License.
Copyright (c) 2022 Leonardo José Tadeu de Araújo, Karolina Rosa Fernandes Beraldo, Daniela Soares Damaceno, Suely Nonogaki, Neuza Kasumi Shirata, Lidia Midori Kimura, Marina Oyafuso, Celso di Loreto, Juliana Mariotti Guerra